Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Govt Approves 1st Use Of Regenerative Medicine In Japan (Japan)

This article was originally published in PharmAsia News

Executive Summary

The Japanese government has given approval to Bioventure Japan Tissue Engineering Co. (J-TEC) to manufacture and sell skin for use in treating serious burns, the first such approval for the use of regenerative medicine in Japan. Skin cells that have been cultured for approximately two weeks are used in the treatment, with technology enabling a 1-sq.-cm sample to grow up to 1,000 times larger. The new skin, once grown, is applied to the damaged part of the body, significantly reducing the chances of rejection compared with procedures using another person's skin. J-TEC also plans to seek approval from the Health Ministry for regenerative treatments to restore the functions of knee cartilage and the epithelium of the cornea. (Click here for more - May Require Paid Subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel